.png){kind=logo}
Recruiting for Rare Disease Trials: Why Volume and Reach Matter Most
Recruiting participants is one of the biggest challenges in any clinical trial. For rare disease studies, that challenge becomes even greater.
Unlike common conditions, rare diseases affect relatively small numbers of people. Patients may be spread across the country, receive care from different healthcare providers, or spend years searching for an accurate diagnosis. Even when an effective study is ready to begin, identifying eligible participants can take far longer than expected.
This is why successful rare disease recruitment depends on more than good planning. It requires volume, reach, and access.
The broader the patient network, the greater the opportunity to identify suitable participants quickly and keep valuable research moving forward.
Why Rare Disease Recruitment Is So Difficult
Every rare disease is different, but many studies face the same recruitment obstacles.
Researchers often encounter:
Small patient populations.
Strict eligibility criteria.
Limited awareness of ongoing studies.
Patients spread across multiple regions.
Few specialist treatment centres.
Each challenge makes recruitment slower and increases the risk of study delays.
Unlike trials for more common conditions, researchers cannot simply add another recruitment campaign and expect immediate results. Finding eligible participants requires a much more targeted approach.
Why Volume Matters
When researchers hear the word "volume", they sometimes think only about recruiting more participants.
In reality, volume means something different.
It refers to having access to a sufficiently large patient population so that even highly specific eligibility criteria can still produce enough suitable candidates.
For example, a study may require participants who:
Have a confirmed diagnosis.
Fall within a specific age range.
Have received certain treatments.
Meet defined clinical criteria.
As these requirements increase, the number of eligible patients becomes much smaller.
Access to larger patient populations increases the likelihood of identifying suitable participants without extending recruitment timelines.
Reach Is Just As Important As Size
A large patient database alone is not enough.
Researchers also need the ability to reach patients through appropriate healthcare pathways.
Rare disease patients often receive care from multiple healthcare professionals throughout their journey, including:
GP practices.
Regional hospitals.
Specialist consultants.
NHS specialist centres.
Without access across these settings, many eligible patients may never become aware of research opportunities.
This is why recruitment strategies must combine scale with strong healthcare partnerships.
Why Early Patient Identification Makes a Difference
Many recruitment delays occur because researchers spend months simply trying to locate eligible participants.
Earlier identification changes the entire recruitment process.
When suitable patients can be identified before recruitment officially begins, research teams can:
Build more accurate recruitment timelines.
Select appropriate participating sites.
Improve feasibility assessments.
Reduce costly delays later in the study.
TrialChoices supports this approach by helping research organisations connect with UK patient populations through established healthcare networks.
Working With Primary Care
GP practices play a much larger role in rare disease recruitment than many people realise.
Although specialist consultants often manage ongoing treatment, GPs frequently remain the patient's first point of contact throughout their healthcare journey.
Primary care records can help identify patients who may be suitable for research while allowing healthcare professionals to introduce opportunities through trusted clinical relationships.
This creates a more efficient and patient-centred recruitment process.
Supporting Specialist Centres
Many rare disease studies rely heavily on specialist hospitals and consultants.
These centres have extensive expertise but often see relatively small numbers of patients.
By combining specialist care with wider access through primary care networks, recruitment becomes significantly stronger.
Researchers benefit from both:
Specialist clinical expertise.
Broader patient reach.
Together, these approaches create a more comprehensive recruitment strategy.
Why Awareness Remains a Challenge
Even when studies are recruiting, patients may never hear about them.
Many people living with rare diseases are unaware that research opportunities exist.
Others may assume they are not eligible.
Improving awareness through healthcare providers, charities, and trusted patient organisations helps ensure more eligible participants have the opportunity to consider involvement.
Better awareness supports both recruitment and patient choice.
Technology Is Improving Rare Disease Recruitment
Modern recruitment relies increasingly on data-driven planning.
Rather than estimating where patients may be located, researchers can make more informed decisions using current healthcare information.
This supports:
Better feasibility planning.
Smarter site selection.
Earlier patient identification.
Faster recruitment timelines.
TrialChoices helps facilitate this process by connecting researchers with UK healthcare providers while supporting efficient identification of suitable patient populations.
Why Collaboration Delivers Better Outcomes
Rare disease recruitment is rarely successful when organisations work in isolation.
The strongest studies involve collaboration between:
Research teams.
GP practices.
Specialist consultants.
NHS organisations.
Patient charities.
Recruitment specialists.
Each partner contributes valuable expertise.
Together, they create recruitment pathways that are faster, more accurate, and more patient-focused.
Looking Ahead
Rare disease research continues to evolve rapidly.
Advances in genomics, personalised medicine, and targeted therapies are creating exciting opportunities for patients with conditions that previously had few treatment options.
However, these innovations depend on successful clinical trials.
As research becomes increasingly specialised, access to large patient populations and broad healthcare networks will become even more important.
Recruitment strategies that prioritise both volume and reach will help ensure promising studies progress without unnecessary delay.
Final Thoughts
Rare disease trials will always present unique recruitment challenges.
But those challenges can be overcome with the right strategy.
Access to larger patient populations, stronger healthcare partnerships, earlier patient identification, and wider geographic reach all contribute to more efficient recruitment.
Rather than relying on isolated recruitment efforts, research teams can benefit from collaborative models that connect healthcare providers, patients, and researchers from the very beginning.
TrialChoices supports this approach by helping researchers access UK patient populations through trusted healthcare networks, making recruitment faster, more targeted, and better prepared for the complexities of rare disease research.
Contact TrialChoices
If your rare disease clinical trial needs help identifying and recruiting eligible UK participants, TrialChoices can support your recruitment strategy.
Call +44 (0)7711 248 610 or email info@trialchoices.org to learn how broader patient access and stronger healthcare partnerships can help accelerate your next clinical study.
Comments